Please review the phone no. indicated, which must contain 9-15 digits and begin with 6,8,9,71,72,73 or 74. For international numbers please indicate 00, followed by the international country code, followed by the phone number.

HAEMATOLOGY AND HAEMOTHERAPY department

TREATMENTS OFFERED AT THE CLÍNICA

We apply monoclonal antibodies, a revolutionary treatment in the therapy for lymphomas. Combined with chemotherapy, this procedure significantly improves the response. In the use of new drugs against lymphoma, we test specific compounds against lymphomatous cells. For myeloma, we use specific compounds against plasma cells.

We are experts in haematopoietic stem cell transplantation for replacing bone marrow.

The Haemostasis and Thrombosis Unit coordinates clinical trials of new drugs to prevent and treat thrombosis and investigates methods for reducing haemorrhaging after surgery as an alternative to blood transfusions.

The application of monoclonal antibodies is one of the treatments that has most revolutionised the therapy for lymphomas.

At the Clinica Universidad de Navarra, this treatment has been jointly administered with chemotherapy to more than a hundred patients, and its use has raised the response rate achieved with just chemotherapy by a significant percentage.

The most widely used antibody is anti-CD20, which binds to lymphoid cells and induces their destruction.

Furthermore, in coordination with the Department of Nuclear Medicine, we have begun to use other types of monoclonal antibodies that add (to the effectiveness of anti-CD20) the action of a radioactive isotope to which they are attached.

Clinical trials on lymphoma and myeloma are currently underway at the Clínica.

In the use of new drugs against lymphoma, the Clinica Universidad de Navarra has several clinical trials underway on specific compounds against lymphomatous cells (Aplidina®, Pixantrone®, Temsirolimus®).

For myeloma, we are currently implementing various clinical trials with specific compounds against plasma cells (Glivec® and synthetic derivatives of thalidomide).

The Bone Marrow Transplantation Programme of the Clinica Universidad de Navarra, under the purview of the Cell Therapy Area, was started in 1989 and has experience with more than 1,200 cases.

This procedure has traditionally been known as bone marrow transplantation because the haematopoietic stem cells were obtained from the bone marrow. Currently, however, the cells are mostly extracted from the blood and occasionally from the umbilical cord and placenta. Therefore, the term haematopoietic progenitor transplantation is preferable.

Research into new drugs and the reduction of post-surgery haemorrhaging.

Thrombosis is the term for the formation of a clot in a blood vessel (artery or vein), which blocks the flow of blood to the tissues.

The Haemostasis and Thrombosis Unit of the Clinica Universidad de Navarra coordinates the implementation of various clinical trials with new drugs in the setting of the prevention and treatment of thrombosis. The Unit is also investigating how to reduce post-surgical haemorrhaging as an alternative to blood transfusion.

We are the first in the world with a clinical trial on transplantation and vaccination against myeloma.

The Clinica Universidad de Navarra, through the Immunotherapy Laboratory of the Cell Therapy Area, is the first centre in the world to start a clinical trial on the treatment of myeloma that includes allogeneic transplantation and the vaccination of donor and recipient with an anti-idiotypic vaccine.

This laboratory has developed specific vaccines against the proteins produced by myeloma cells, while simultaneously using other immunotherapy strategies with dendritic cells against myeloma.